

segmented RNA virus or belongs to the family paramyxoviridae. The new claims are fully supported by the instant specification. For example, attention is drawn to page 30, lines 10-30, of the instant specification.

New Claim 12 is drawn to a vaccine preparation comprising the genetically manipulated viruses of the instant invention

New Claims 13 to 16 are drawn to a process for the preparation of an infectious, non-segmented negative stranded RNA virus. The new claims are fully supported by the instant specification, e.g., see page 19, line 13 to page 20, line 30.

The new claims presented herein do not constitute new matter.

Entry of the foregoing amendments and remarks is respectfully requested.

Date February 28, 2001

Respectfully submitted,

by: *Jaqueline Ben*  
*Laura A. Coruzzi*  
Laura A. Coruzzi (Reg. No.)

Reg No. 43,492  
30,742

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

## APPENDIX A

Please add new Claims 7 to 16 as follows:

7. (new) A genetically manipulated, infectious virus of the paramyxoviridae family wherein the virus genome comprises a modification wherein the modification is selected from an insertion, substitution or deletion.

8. (new) The genetically manipulated, infectious virus of Claim 8, the genome of which has been modified to encode a heterologous sequence.

9. (new) The virus of Claim 7 or 8 wherein the virus is a parainfluenza virus.

10. (new) The virus of Claim 7 or 8 wherein the virus is a respiratory syncytial virus.

11. (new) A genetically manipulated, infectious, non-segmented, negative-stranded RNA virus wherein the virus genome comprises a modification wherein the modification is selected from an insertion, substitution or deletion.

12. (new) A vaccine comprising the genetically manipulated viruses of Claims 7, 8, or 11 and a pharmaceutically acceptable carrier.

13. (new) A method for rescuing a genetically manipulated non-segmented negative-stranded RNA virus comprising

introducing into a host cell expressing a heterologous RNA polymerase:

- (a) one or more DNA molecules encoding the virus N, P and L proteins operably linked to a polymerase binding site;
  - (b) a DNA molecule comprising the cDNA of the non-segmented negative stranded RNA virus wherein the cDNA encodes the entire genome of the virus or is modified by the incorporation of a mutation or a heterologous sequence, and wherein the cDNA is transcribed by a heterologous RNA polymerase; and
- isolating the virus produced by the cell.

14. (new) The method of Claim 13 wherein the virus is from the paramyxoviridae family.

15. (new) The method of Claim 14 wherein the virus is parainfluenza virus.

16. (new) The method of Claim 14 wherein the virus is a respiratory syncytial virus –